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SUMMARY 
In in open prospective trial five cases of mania identified as lithium non-responders were treated with li-
thium - carbamazepine conciliation. The prophylactic efficacy of this combination wai also studied. The combina-
tion proved to be therapeutically and prophylactically effective without significant side effects. The finding* and 
relevant clinical issues are discussed. 
Lithium carbonate is the most com-
monly used drug in treatment of mania. Al-
though it's therapeutic and prophylactic ef-
ficacy Tias been proved, the fact that a size-
able number of patients do not respond to 
lithium has necessitated the search for an 
adjunct or alternative in treatment of 
mania. Intolerable side effects or neuroto-
xicity observed with lithium, especially in 
combination with neuroleptics, are other 
reasons for an effort to look for therapeutic 
and/or prophylactic efficacy of other drugs 
in mania Flupenthixol, Sodium Valporate 
and it's derivative depamide, Verapramil 
and Carbamazepine being the best estab-
lished (Nolen 1983). 
Carbamazepine (CBZ) has been studied 
as a single drug and in combination with li-
thium. Following their reports in the early 
1970s of the antimanic effects of carbama-
zepine, Okuma ct al (1979) demonstrated 
in a multicentred double blind study that 
carbamazepine was as effective as chlorpro-
mazine in treatment of mania. Ballerger 
and Post (1980) showed carbamazepine to 
be an effective antimanic agent. Lipinsky 
and Pope (1982), Keishing (1983) and Desai 
et al (1983) identified manics in whom li-
thium or carbamazepine alone were thera-
peutically ineffective but in whom the 
combination of two drugs proved to be 
therapeutically successful. Use of carbama-
zepine for prophylaxsis in manic-depres-
sive illness or bipolar disorders has been de-
monstrated as a single drug (Folks et al. 
1982) and in combination with lithium, 
neuroleptics or antidepressants (Kishimoto 
et al. 1983). The role of carbamazepine ad-
ministered alone or in combination with li-
thium or neuroleptics in the therapy and/or 
prophylaxis of lithium-resistant bipolar ill-
ness has been further studied and con-
firmed (Post ct aL 1984, Nolen 1983, Faw-
cett and Kravitz 1985, Elphick 1985). 
Material and Methods 
A nine month open, prospective study 
was conducted on all patients receiving an 
ICD - 9 diagnosis of manic depressive psy-
chosis, mania (ICD codes 296.0 and 2962). 
These patients were treated with lithium 
carbonate and neuroleptics and screened 
for nonresponse which was defined as "in-
significant or no change in the clinical sta-
tus despite maintaining a serum lithium le-
vel of \2 to 1.5 meq/L for a period of three 
weeks". In such cases, carbamazepine in a 
dose of 400 to 600 mgs/day was added to 
the therapeutic regime and neuroleptics 
were gradually withdrawn. Recovery was 
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defined as the absence of uunic or hypo-
manic symptoms on clinical examination. 
The patients have been followed up for 
observing the prophylactic efficacy of li-
thium - carbamazepine combination. 
Results 
Of 30 patients screened, 5(17%) were 
identified as non-rcspondcrs for the current 
episode. There were 4 females and 1 male, 
with ages ranging from 18-26 years. All but 
one patient had experienced several previ-
ous episodes of mania which had been resis-
tant to lithium thus needing adjunctive 
high-dose neuroleptics, ECT and rcserpinc 
leading to severe extrapyramidal reaction 
in one and neurotoxicity in two. 
In the current manic episode, once car-
bamazepine was started improvement was 
obtained in all five patients within just 2 
weeks and was complete over the suc-
ceeding 2 weeks. Very tew side effects like 
transient giddiness, drowsiness and /or nau-
sea were noticed. 
The other two patients (III and IV) were 
maintained on lithium alone for prophylax-
sis one patient (V) was lost to followup 
spanning 10 to 24 months. The two patients 
who did not respond to therapy with li-
thium in acute mania have also maintained 
improvement on lithium prophylaxsis. 
Discussion 
This report describes patients who did 
not respond to lithium for therapy of acute 
mania being successfully treated with addi-
tion of carbamazepine. The need for using 
neuroleptics in high doses, in addition to li-
thium noticed in earlier episodes leading to 
severe side effects, was also avoided. The li-
thium - carbama7.epine effect was found to 
initiate in 2 weeks' time with complete re-
covery in 4 weeks. There are reports of dis-
tressing and potentially serious side effects 
.of carbamazepine alone or in combination 
with lithium (Choudhary and Waters 
1983, Shukla ct al 1984, Kluitan et al 1985, 
Elphick 1985). We did not find significant 
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Of the three patients who were on li-
thium prophylaxis before the current manic 
episode one had history of non-compliance 
whereas two (Patients I and II) were on re-
gular followup and medication along with 
periodic serum lithium estimations. These 
two patients can be said to have not re-
sponded to prophylactic lithium and were 
maintained on lithium and 400 mgs/day of 
(.»rl).i'iiazepine for further prophylaxsis. 
side effects supporting the view of Okuma 
ct al (1979), Ballcrger and Post (1980) and 
Nolen (1983) that carbamazepine is a safe 
drug in mania. 
The followup findings suggest that li-
thium carbamazepine combination is also 
useful in patients who do not respond to 
prophylactic lithium. Two cases of thera-
peutic non-response to lithium showing 
good response to lithium Prophylaxis NJMESH G. DKAI ET AL 161 
make an interesting observation and raise 
important treatment issues. It is possible 
that therapeutic non-responders to lithium 
may be prophylactic responders to lithium? 
Can the patients who may require 
lithium - carbamazepine combination for 
treatment of acute mania be maintained on 
lithium alone for Prophylaxis ? Our finding 
suggests an answer in affirmative. 
Certain lacunae exist in literature in gen-
eral and in our study as well which merit at-
tention in future studies. Lithium non-re-
sponse both therapeutic and prophylactic 
needs to be better defined in terms of the time 
set and possibly with erythrocyte/serum li-
thium ratio instead of serum lithium as an in-
dex. Therapeutic and prophylactic efficacy 
needs to be assessed more objectively using 
appropriate rating scales rather than on clini-
cal grounds. Serum levels of carbamazepine or 
its most active metabolite carbamazepine -
10, 11 Epoxide (CBZ-E) require investiga-
tion as suggested by Post et al (1984). Carba-
mazepine needs to be studied individually in 
comparison to lithium and the combination 
for therapy and prophylaxis. 
These limitations notwithstanding, our 
open trial suggests a definite role for lithium -
carbamazepine in lithium non-responders for 
therapy and prophylaxis in mania. 
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